

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> <b>Starpharma Holdings Ltd</b>
<b>ABN</b> <b>20 078 532 180</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Jacinth K Fairley
<b>Date of last notice</b>	6 June 2013

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	2 October 2013
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. 1,769,197 Ordinary Shares (direct)</li> <li>2. 55,000 Ordinary Shares (indirect) Dr Ian Fraser</li> <li>3. 960,000 Performance Rights (SPLAK)</li> </ol>
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	200,000 Ordinary fully paid shares (direct)
<b>Number disposed</b>	Nil Ordinary Shares 400,000 Performance Rights (SPLAK) (200,000 vested; 200,000 lapsed)
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> <li>1. 1,969,197 Ordinary Shares (direct)</li> <li>2. 55,000 Ordinary Shares (indirect) Dr. Ian Fraser</li> <li>3. 560,000 Performance Rights (SPLAK)</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>(i) Allotment of 200,000 ordinary fully paid shares following vesting of Performance Rights on 30 September 2013.</p> <p>(These shares will be subject to a holding lock until 30 Sep 2014 provided that the shares may be released early if certain events occur, in accordance with the Rules of the Starpharma Employee Performance Rights Plan.)</p> <p>(ii) Lapse of 200,000 Performance Rights due to the applicable vesting conditions not being satisfied.</p>

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.